Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Immunohistochemical correlation of matrix metalloproteinase-2 and tissue inhibitors of metalloproteinase-2 in tobacco associated epithelial dysplasia.

Bajracharya D, Shrestha B, Kamath A, Menon A, Radhakrishnan R.

Dis Markers. 2014;2014:197813. doi: 10.1155/2014/197813. Epub 2014 Jan 27.

2.

[Expression of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in the hepatocellular carcinomas].

Wei QY, Wu YQ, Fan SQ.

Hunan Yi Ke Da Xue Xue Bao. 2003 Jun;28(3):212-6. Chinese.

PMID:
14653069
3.

Expression of matrix metalloproteinases (MMP-1 and -2) and their inhibitors (TIMP-1, -2 and -3) in oral lichen planus, dysplasia, squamous cell carcinoma and lymph node metastasis.

Sutinen M, Kainulainen T, Hurskainen T, Vesterlund E, Alexander JP, Overall CM, Sorsa T, Salo T.

Br J Cancer. 1998 Jun;77(12):2239-45.

4.

[Expression and significance of matrix metalloproteinase and tissue inhibitor of matrix metalloproteinase in non-melanoma skin cancer].

Fu XR, Zhang C, Chen CY, Zhang L, Wang LX, Wang BH, Liu XY, Zhang MZ.

Zhonghua Zhong Liu Za Zhi. 2012 May;34(5):369-73. doi: 10. 3760/cma.j.issn.0253-3766.2012.05.011. Chinese.

PMID:
22883459
5.

Expression of matrix metalloproteinase-2 and its tissue inhibitor-2 in fetal and neoplastic thyroid tissue and their significance as diagnostic and prognostic markers in papillary carcinoma.

Marečko I, Cvejić D, Tatić S, Dragutinović V, Paunović I, Savin S.

Cancer Biomark. 2011-2012;11(1):49-58. doi: 10.3233/CBM-2012-0258.

PMID:
22820140
6.

May High MMP-2 and TIMP-2 Expressions Increase or Decrease the Aggressivity of Oral Cancer?

Shrestha B, Bajracharya D, Byatnal AA, Kamath A, Radhakrishnan R.

Pathol Oncol Res. 2017 Jan;23(1):197-206. doi: 10.1007/s12253-016-0149-3. Epub 2016 Nov 16.

PMID:
27853937
7.
8.

Expression of matrix metalloproteinases (MMP-1, MMP-2 and MMP-9) and their inhibitors (TIMP-1 and TIMP-2) in oral submucous fibrosis.

Rajendran R, Rajeesh MP, Shaikh S, Shanthi, Pillai MR.

Indian J Dent Res. 2006 Oct-Dec;17(4):161-6.

9.
10.

The impact of differential expression of extracellular matrix metalloproteinase inducer, matrix metalloproteinase-2, tissue inhibitor of matrix metalloproteinase-2 and PDGF-AA on the chronicity of venous leg ulcers.

Mwaura B, Mahendran B, Hynes N, Defreitas D, Avalos G, Adegbola T, Adham M, Connolly CE, Sultan S.

Eur J Vasc Endovasc Surg. 2006 Mar;31(3):306-10.

11.

The role of matrix metalloproteinase MMP-9 and TIMP-2 tissue inhibitor of metalloproteinases as serum markers of bladder cancer.

Ramón de Fata F, Ferruelo A, Andrés G, Gimbernat H, Sánchez-Chapado M, Angulo JC.

Actas Urol Esp. 2013 Sep;37(8):480-8. doi: 10.1016/j.acuro.2013.05.004. Epub 2013 Jul 31.

PMID:
23916137
12.
13.

Effects of basic fibroblast factor (bFGF) on MMP-2, TIMP-2, and type-I collagen levels in human lung carcinoma fibroblasts.

Nakoman C, Resmi H, Ay O, Acikel U, Atabey N, Güner G.

Biochimie. 2005 Mar-Apr;87(3-4):343-51.

PMID:
15781321
14.

[Expression and significance of matrix metalloproteinase and tissue inhibitor of metalloproteinase in nasal cavity squamous cell carcinoma].

Zheng Y, Ding J, Wang CL, Jiao SS, Qu LM, Bahargul, Bao H, Chen X.

Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2011 Apr;46(4):299-302. Chinese.

PMID:
21624249
15.
16.

Positive correlation between inhibitors of matrix metalloproteinase 1 and matrix metalloproteinases in malignant ovarian tumor tissues.

Kikkawa F, Tamakoshi K, Nawa A, Shibata K, Yamagata S, Yamagata T, Suganuma N.

Cancer Lett. 1997 Nov 25;120(1):109-15.

PMID:
9570393
17.
19.

Expression of MMP-2, -7, -9, MT1-MMP and TIMP-1 and -2 has no prognostic relevance in patients with advanced epithelial ovarian cancer.

Brun JL, Cortez A, Lesieur B, Uzan S, Rouzier R, Daraï E.

Oncol Rep. 2012 Apr;27(4):1049-57. doi: 10.3892/or.2011.1608. Epub 2011 Dec 22.

20.

Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma.

Manenti L, Paganoni P, Floriani I, Landoni F, Torri V, Buda A, Taraboletti G, Labianca R, Belotti D, Giavazzi R.

Eur J Cancer. 2003 Sep;39(13):1948-56.

PMID:
12932675

Supplemental Content

Support Center